{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:37:13Z","timestamp":1793900233534,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2025 Beijing Jishuitan Hospital Youth Fund","award":["QN202515"],"award-info":[{"award-number":["QN202515"]}]},{"name":"Beijing High-level Public Health Technical Talent Construction Project","award":["Subject Backbone 02-19"],"award-info":[{"award-number":["Subject Backbone 02-19"]}]},{"name":"Capital Health Development Research Special Project","award":["2022-1-5082"],"award-info":[{"award-number":["2022-1-5082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15136-2","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:56:00Z","timestamp":1762167360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic efficacy of multiple neoadjuvant regimens involving targeted therapy, immunotherapy and chemotherapy in gastric cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Chen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gailing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"3","key":"15136_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"15136_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamasurg.2022.0182","volume":"157","author":"GZ Li","year":"2022","unstructured":"Li GZ, Doherty GM, Wang J. Surgical management of gastric cancer: a review. JAMA Surg. 2022;157(5):446\u201354.","journal-title":"JAMA Surg"},{"issue":"1","key":"15136_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"15136_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"15136_CR5","volume":"1877","author":"Y Chen","year":"2022","unstructured":"Chen Y, Bai B, Ying K, Pan H, Xie B. Anti-PD-1 combined with targeted therapy: theory and practice in gastric and colorectal cancer. Biochimica et Biophysica Acta (BBA). 2022;1877(5):188775.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"3","key":"15136_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10120-022-01286-w","volume":"25","author":"H Hasegawa","year":"2022","unstructured":"Hasegawa H, Shitara K, Takiguchi S, et al. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer. 2022;25(3):619\u201328.","journal-title":"Gastric Cancer"},{"issue":"7","key":"15136_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747\u201358.","journal-title":"Drugs"},{"issue":"6","key":"15136_CR8","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1245\/s10434-023-13143-w","volume":"30","author":"S Li","year":"2023","unstructured":"Li S, Xu Q, Dai X, et al. Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2023;30(6):3594\u2013602.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15136_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01773-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen X, Xu H, Chen X, et al. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study. Signal Transduct Target Ther. 2024;9(1):73.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"15136_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, Gotze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol. 2024;42(4):410\u201320.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15136_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"S7","key":"15136_CR12","doi-asserted-by":"publisher","first-page":"S1106","DOI":"10.1016\/j.annonc.2022.07.1338","volume":"33","author":"LZ Min","year":"2022","unstructured":"Min LZ, Liu N, Zhou Y, Niu Z. Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy. Ann Oncol. 2022;33(S7):S1106.","journal-title":"Ann Oncol"},{"issue":"S2","key":"15136_CR13","doi-asserted-by":"publisher","first-page":"S852","DOI":"10.1016\/j.annonc.2023.09.1425","volume":"24","author":"C Li","year":"2023","unstructured":"Li C, Zheng Y, Shi Z, et al. Perioperative camrelizumab (C) combined with Rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase III trial (DRAGON IV). Ann Oncol. 2023;24(S2):S852.","journal-title":"Ann Oncol"},{"issue":"3","key":"15136_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.2024.42.3_suppl.312","volume":"42","author":"Z Peng","year":"2024","unstructured":"Peng Z, Zhang XT, Liang H, et al. Atezolizumab and trastuzumab plus chemotherapy in patients with HER2\u2009+\u2009locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: a multicenter, randomized, open-label phase II study. J Clin Oncol. 2024;42(3):312.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15136_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"15136_CR16","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"15136_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"9","key":"15136_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"15136_CR19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.4251\/wjgo.v16.i4.1281","volume":"16","author":"ZH Bao","year":"2024","unstructured":"Bao ZH, Hu C, Zhang YQ, et al. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol. 2024;16(4):1281\u201395.","journal-title":"World J Gastrointest Oncol"},{"key":"15136_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae005","volume":"12","author":"H Cui","year":"2024","unstructured":"Cui H, Liang W, Cui J, et al. Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer: a propensity score-matched analysis in China. Gastroenterol Rep. 2024;12:goae005.","journal-title":"Gastroenterol Rep"},{"key":"15136_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1322152","volume":"15","author":"JL Lin","year":"2024","unstructured":"Lin JL, Lin M, Lin GT, et al. Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion. Front Immunol. 2024;15:1322152.","journal-title":"Front Immunol"},{"key":"15136_CR22","doi-asserted-by":"crossref","unstructured":"Sun YQ, Zhong Q, Lv CB et al. The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicenter Real-world clinical study. Int J Surg. 2024;110(8):4830-8.","DOI":"10.1097\/JS9.0000000000001468"},{"key":"15136_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003028","author":"G Xu","year":"2024","unstructured":"Xu G, Liu T, Shen J, Guan Q. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs. chemotherapy alone in HER2(-) locally advanced gastric cancer: a propensity score-matched cohort study. Chin Med J (Engl). 2024. https:\/\/doi.org\/10.1097\/CM9.0000000000003028.","journal-title":"Chin Med J (Engl)"},{"key":"15136_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","volume":"14","author":"Q Jiang","year":"2023","unstructured":"Jiang Q, Liu W, Zeng X, et al. Safety and efficacy of Tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort. Front Immunol. 2023;14:1122121.","journal-title":"Front Immunol"},{"key":"15136_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1078196","volume":"13","author":"J Su","year":"2022","unstructured":"Su J, Guo W, Chen Z, et al. Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: a retrospective cohort study. Front Immunol. 2022;13:1078196.","journal-title":"Front Immunol"},{"key":"15136_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101657","volume":"31","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang C, Hou H, et al. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: a single-centre retrospective study. Transl Oncol. 2023;31:101657.","journal-title":"Transl Oncol"},{"issue":"1","key":"15136_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","volume":"15","author":"JX Lin","year":"2024","unstructured":"Lin JX, Tang YH, Zheng HL, et al. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. Nat Commun. 2024;15(1):41.","journal-title":"Nat Commun"},{"issue":"2","key":"15136_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5230\/jgc.2023.23.e17","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, Wang Z, Zhao Y, Wang F, Neoadjuvant. PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy in treating patients with locally advanced gastric cancer: A Prospective, cohort study. J Gastric Cancer. 2023;23(2):328\u201339.","journal-title":"J Gastric Cancer"},{"issue":"8","key":"15136_CR29","first-page":"3559","volume":"13","author":"H Xiong","year":"2023","unstructured":"Xiong H, Li Y, Neoadjuvant. PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer. Am J Cancer Res. 2023;13(8):3559\u201370.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"15136_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s11845-022-03075-x","volume":"192","author":"Y Sun","year":"2023","unstructured":"Sun Y, Fan Y, Ye Z, Dong J, Zhang L, Peng Y. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study. Ir J Med Sci. 2023;192(3):1033\u201340.","journal-title":"Ir J Med Sci"},{"issue":"4","key":"15136_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11562","volume":"24","author":"Z Wang","year":"2022","unstructured":"Wang Z, He T, Yu D, Qin X, Geng A, Yang H. Neoadjuvant apatinib plus tegafur\/gimeracil\/oteracil potassium (S\u20131)\/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma. Exp Ther Med. 2022;24(4):625.","journal-title":"Exp Ther Med"},{"key":"15136_CR32","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/CMAR.S304093","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang B, Yang J, Zhang J, Zhang W. Perioperative safety and effectiveness of neoadjuvant therapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel plus apatinib in locally advanced gastric cancer. Cancer Manag Res. 2021;13:2279\u201386.","journal-title":"Cancer Manag Res"},{"issue":"S6","key":"15136_CR33","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2020.10.175","volume":"31","author":"YH Tang","year":"2020","unstructured":"Tang YH, Wang FH, Lin GJ, et al. A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer. Ann Oncol. 2020;31(S6):S1300.","journal-title":"Ann Oncol"},{"issue":"S4","key":"15136_CR34","doi-asserted-by":"publisher","first-page":"S905","DOI":"10.1016\/j.annonc.2020.08.1940","volume":"31","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang D, Zhao Q, Zhang HW, Zheng ZC. A prospective, multicenter, non-randomized, controlled trial of apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer. Ann Oncol. 2020;31(S4):S905.","journal-title":"Ann Oncol"},{"issue":"8","key":"15136_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747\u201395.","journal-title":"Cancer Commun"},{"key":"15136_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020. https:\/\/doi.org\/10.1126\/science.aax0182.","journal-title":"Science"},{"issue":"1","key":"15136_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2772-5","volume":"16","author":"K Zou","year":"2016","unstructured":"Zou K, Yang S, Zheng L, Yang C, Xiong B. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review. BMC Cancer. 2016;16(1):737.","journal-title":"BMC Cancer"},{"issue":"2","key":"15136_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0493-6","volume":"18","author":"SC Kamran","year":"2016","unstructured":"Kamran SC, Hong TS, Wo JY. Advances in the management of gastric and gastroesophageal cancers. Curr Oncol Rep. 2016;18(2):13.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"15136_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10120-021-01182-9","volume":"24","author":"G Roviello","year":"2021","unstructured":"Roviello G, Aprile G, D\u2019Angelo A, et al. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? Gastric Cancer. 2021;24(4):765\u201379.","journal-title":"Gastric Cancer"},{"issue":"1","key":"15136_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02841-7","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Qin S, Wen L, et al. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study. BMC Med. 2023;21(1):173.","journal-title":"BMC Med"},{"issue":"7","key":"15136_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16240","volume":"4","author":"JX Lin","year":"2021","unstructured":"Lin JX, Xu YC, Lin W, et al. Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial. JAMA Netw Open. 2021;4(7):e2116240.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"15136_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"10294","key":"15136_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"5","key":"15136_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"2","key":"15136_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15136_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74\u201388.","journal-title":"Immunity"},{"issue":"21","key":"15136_CR47","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/0008-5472.CAN-12-2236","volume":"72","author":"R Ramakrishnan","year":"2012","unstructured":"Ramakrishnan R, Huang C, Cho HI, et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012;72(21):5483\u201393.","journal-title":"Cancer Res"},{"issue":"7890","key":"15136_CR48","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"key":"15136_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016817","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817.","journal-title":"Front Immunol"},{"issue":"9","key":"15136_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20(9):604\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"15136_CR51","first-page":"86","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86\u2013104.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15136_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15136-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15136-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15136-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:03:17Z","timestamp":1762171397000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15136-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15136"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15136-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted based on previously published studies, the necessity for informed consent and institutional review board approval was exempted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1694"}}